This inventor holds 1 USPTO granted patent. Top assignee: Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Zhankun Yang: Innovator in Pharmaceutical Technology
Introduction
Zhankun Yang is a notable inventor based in Hebei, China. He has made significant contributions to the field of pharmaceutical technology, particularly in the development of aldose reductase inhibitors. His work focuses on improving the solubility and stability of medicinal compounds.
Latest Patents
Zhankun Yang holds a patent for a "Salt of aldose reductase inhibitor, and preparation method and application thereof." This invention presents a salt of an aldose reductase inhibitor, which can be prepared in a crystal form. The salt demonstrates notably improved solubility compared to the original compound, along with lower hygroscopicity, allowing for a more stable existence. This advancement facilitates the formulation of effective medicines.
Career Highlights
Zhankun Yang is associated with Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. His role in the company has been pivotal in advancing pharmaceutical innovations. He has contributed to the development of new therapeutic agents that address critical health issues.
Collaborations
Zhankun Yang has worked alongside talented colleagues, including Hanyu Yang and Pengfei Li. Their collaborative efforts have fostered a productive environment for innovation and research.
Conclusion
Zhankun Yang's contributions to pharmaceutical technology exemplify the impact of innovative thinking in medicine. His patent on aldose reductase inhibitors highlights the importance of improving drug formulations for better therapeutic outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile